Literature DB >> 10634130

Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.

A Gaedigk1, R R Gotschall, N S Forbes, S D Simon, G L Kearns, J S Leeder.   

Abstract

Cytochrome P4502D6 (CYP2D6) is a highly polymorphic gene locus with > 50 variant alleles which lead to a wide range in enzymatic activity. So called poor metabolizers are carriers of any two non-functional alleles of the CYP2D6 gene. CYP2D6 genotyping is cumbersome and the question of how much genotyping is necessary for an accurate phenotype prediction is still debated. The goal of this study was to determine the optimum amount of genotyping required to accurately predict the phenotype at a reasonable cost in a white North American population. To address this issue, we designed a polymerase chain reaction (PCR)/restriction fragment length polymorphism-based genotyping strategy to detect 'key' mutations linked to extensive metabolizer or poor metabolizer associated alleles in combination with extra-long PCR (XL-PCR). All mutations with the exception of gene deletions and duplications are detectable by simple restriction digestion analysis and agarose gel electrophoresis. In addition, we utilized a genotyping algorithm based on our own and published allele frequency data and phenotype analysis to calculate the probability of a correct genotype (and thus, phenotype) assignment. As little as one XL-PCR reaction followed by a maximum of six reamplification reactions allows an accurate prediction of an individual's genotype to 99.15%. As few as four reamplification reactions identify 97.9% of poor metabolizer individuals. We evaluated our model in 208 white North Americans by testing for the presence of 'key' mutations linked to CYP2D6*2, *3, *4, *6, *7, *8, *9, *10, *11, *12, *15, *17 and *18 alleles and the *5, *13 and *16 gene deletions. For all individuals, the correct phenotype has been predicted. Discordant phenotype assignment occurred in only two individuals which subsequently was attributed to CYP2D6 inhibition by concomitant drug therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10634130     DOI: 10.1097/01213011-199912000-00002

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  44 in total

1.  Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.

Authors:  Myo-Kyoung Kim; Joo-Youn Cho; Hyeong-Seok Lim; Kyoung-Seop Hong; Jae-Yong Chung; Kyun-Seop Bae; Dal-Seok Oh; Sang-Goo Shin; Sang-Hun Lee; Dong-Ho Lee; Bumchan Min; In-Jin Jang
Journal:  Eur J Clin Pharmacol       Date:  2003-05-01       Impact factor: 2.953

2.  Allelic and genotype frequencies of catechol-O-methyltransferase (Val158Met) and CYP2D6*10 (Pro34Ser) single nucleotide polymorphisms in the Philippines.

Authors:  Michael O Baclig; Rey Z Predicala; Cynthia A Mapua; Jingky P Lozano-Kühne; Maria Luisa G Daroy; Filipinas F Natividad; Francis O Javier
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

3.  Identification of CYP2D6 impaired functional alleles in Mexican Americans.

Authors:  Huai-Rong Luo; Andrea Gaedigk; Vasileios Aloumanis; Yu-Jui Yvonne Wan
Journal:  Eur J Clin Pharmacol       Date:  2005-11-08       Impact factor: 2.953

Review 4.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

5.  The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements.

Authors:  Andrea Gaedigk; Christa Coetsee
Journal:  Eur J Clin Pharmacol       Date:  2008-01-17       Impact factor: 2.953

6.  Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.

Authors:  Kyoung Soo Lim; Joo-Youn Cho; In-Jin Jang; Bo-Hyung Kim; JaeWoo Kim; Ji-Young Jeon; Yu-Mi Tae; SoJeong Yi; SoYoung Eum; Sang-Goo Shin; Kyung-Sang Yu
Journal:  Br J Clin Pharmacol       Date:  2008-07-24       Impact factor: 4.335

7.  Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population.

Authors:  Carmelo Orengo-Mercado; Bianca Nieves; Lizbeth López; Nabila Vallés-Ortiz; Jessicca Y Renta; Pedro J Santiago-Borrero; Carmen L Cadilla; Jorge Duconge
Journal:  J Pharmacogenomics Pharmacoproteomics       Date:  2013-03-27

8.  CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.

Authors:  Andrea Gaedigk; Uwe Fuhr; Charlene Johnson; L Anick Bérard; Dianne Bradford; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-01       Impact factor: 2.533

Review 9.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

Review 10.  Cytochrome P450 2D6.

Authors:  Ryan P Owen; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.